SCHEMBL5764779

SCHEMBL5764779

CCc1nc(Cc2ccc(F)c(F)c2)sc1C1CCNCC1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR6 P50406 2/20 0.40
CCR5 P51681 4/20 0.37
GABRA1 P14867 4/20 0.36
GABRG2 P18507 1/20 0.36
GABRB3 P28472 1/20 0.36
PSEN1 P49768 1/20 0.36
PSEN2 P49810 1/20 0.36
APH1B Q8WW43 1/20 0.36
NCSTN Q92542 1/20 0.36
APH1A Q96BI3 1/20 0.36
PSENEN Q9NZ42 1/20 0.36
SOS1 Q07889 2/20 0.35
CDK9 P50750 2/20 0.35
USP25 Q9UHP3 1/20 0.35
GABRB2 P47870 3/20 0.34
CCNT1 O60563 1/20 0.34
APP P05067 1/20 0.33
OPRM1 P35372 1/20 0.33
GPR4 P46093 1/20 0.33
HTR3A P46098 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5762754 0.87 HTR6 (0.47) HTR6GABRA1GABRG2GABRB3PSEN1
SCHEMBL5764678 0.87 CCR5 (0.40) CCR5GABRA1GABRG2GABRB3OPRM1
SCHEMBL5762055 0.86 CCR5 (0.39) HTR6CCR5GABRA1GABRG2GABRB3
SCHEMBL5764902 0.85 CCR5 (0.47) HTR6CCR5GABRA1GABRG2GABRB3
SCHEMBL5764687 0.85 CCR5 (0.38) HTR6CCR5GABRA1GABRG2GABRB3
SCHEMBL5764697 0.85 HTR6 (0.39) HTR6CCR5GABRA1GABRG2GABRB3
SCHEMBL5765334 0.84 HTR6 (0.40) HTR6CCR5GABRA1GABRG2GABRB3
SCHEMBL5762631 0.84 CCR5 (0.41) CCR5GABRA1GABRG2GABRB3GABRB2
SCHEMBL5765303 0.83 CCR5 (0.38) CCR5GABRA1GABRG2GABRB3GABRB2
SCHEMBL5764323 0.83 HTR6 (0.43) HTR6CCR5GABRA1GABRG2GABRB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1192133-B1 N-CYCLOPENTYL MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY MERCK & CO INC (US) 2006-11-02 EP disclosed
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-6538002-B1 In particular, these compounds are useful as modulators of the chemokine receptors CCR-5 and/or CCR-3. as antiinflammatory agents MERCK & CO., INC. 2003-03-25 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
US-6432981-B1 BLOCKS HUMAN IMMUNODEFICIENCY VIRUS (HIV) FROM ENTERING CELLS; AUTOIMMUNE DISEASES; ANTIALLERGENS, ANTIINFLAMMATORY AND ANTIASTHMATIC AGENTS MERCK & CO., INC. 2002-08-13 US disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 HTR6 1057/4885CCR5 3/4885GABRA1 1033/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.